Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 9INDUSTRY 5NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 513Neoplasms 381Lymphoma 341Prostatic Neoplasms 291Melanoma 284Carcinoma, Non-Small-Cell Lung 278Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Lung Neoplasms 257Leukemia, Lymphocytic, Chronic, B-Cell 249Leukemia, Myeloid, Acute 236Leukemia 235Lymphoma, Non-Hodgkin 227Colonic Neoplasms 226Ovarian Neoplasms 208Lymphoma, Large B-Cell, Diffuse 208Multiple Myeloma 207Brain Neoplasms 206Colorectal Neoplasms 203Lymphoma, Follicular 201Rectal Neoplasms 194Burkitt Lymphoma 183Neoplasm Metastasis 180Carcinoma, Renal Cell 172Glioblastoma 169Sarcoma 168Lymphoma, Mantle-Cell 166Pancreatic Neoplasms 158Lymphoma, B-Cell, Marginal Zone 145Unspecified Adult Solid Tumor, Protocol Specific 141Hodgkin Disease 141

Interventions

ibrutinib 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Prolymphocytic, B-Cell × Clear all
NCT01886859 2022-09-26

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡